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ABTRACT 
A third of the human genome encodes N-glycosylated proteins. These are co-
translationally translocated into the lumen/membrane of the endoplasmic 
reticulum (ER) where they fold and assemble before they are transported to their 
final destination. Here we show that calnexin, a major ER chaperone involved in 
glycoprotein folding is palmitoylated and that this modification is mediated by the 
ER palmitoyltransferase DHHC6. This modification leads to the preferential 
localization of calnexin to the perinuclear rough ER, at the expense of ER 
tubules. Moreover, palmitoylation mediates the association of calnexin with the 
ribosome-translocon complex (RTC) leading to the formation of a supercomplex 
that recruits the actin cytoskeleton, leading to further stabilization of the 
assembly. When formation of the calnexin-RTC supercomplex was affected by 
DHHC6 silencing, mutation of calnexin palmitoylation sites or actin 
depolymerization, folding of glycoproteins was impaired. Our findings thus show 
that calnexin is a stable component of the RTC in a manner that is exquisitely 
dependent on its palmitoylation status. This association is essential for the 
chaperone to capture its client proteins as they emerge from the translocon, 
acquire their N-linked glycans and initiate folding. 
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INTRODUCTION 
More than a third of the human genome encodes for membrane proteins or 
proteins secreted into the extracellular milieu. These proteins are generally 
synthesized with an N-terminal signal sequence that targets the translating 
ribosome to the endoplasmic reticulum (ER) where it docks onto the translocon 
(Braakman & Bulleid, 2011). The translocon is a multiprotein transmembrane 
complex composed of a central sec61α tetrameric pore to which associate a 
number of accessory proteins such as sec61ß, sec62 or the TRAP (translocon-
associated protein) complex (Skach, 2007). Once the ribosome is docked onto 
the translocon, synthesis resumes and the nascent protein is co-translationally 
translocated through the sec61 channel to the lumen of the ER. As the newly 
synthesized protein emerges from the translocon, it is handled sequentially by a 
variety of enzymes, in particular leading to the addition of N-linked glycans and 
the formation of disulfide bonds, which together increase the solubility and 
stability of the protein, as well as chaperones that promote folding by preventing 
aggregation of intermediates. 
N-glycosylation is carried out by the oligosaccharyltransferase (OST), a 
hetero-oligomeric complex, which associates with the ribosome-translocon 
complex (RTC), allowing the addition of the branched oligosaccharide co- or 
post-translationally (Chavan & Lennarz, 2006). To prevent aggregation or too 
rapid folding, which might hinder N-glycosylation (McGinnes & Morrison, 1994), 
the OST (Li et al, 2008) and the general chaperone BiP/Grp78 (Hammond & 
Helenius, 1994) maintain the polypeptide in a folding competent state.  
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Glycoproteins are subsequently handled by the lectin binding chaperones 
calnexin and calreticulin (Aebi et al, 2010). Calnexin is a type I membrane protein 
and calreticulin is its soluble homologue. Proteins that undergo N-glycosylation 
acquire en bloc a glucose3-mannose9-N-acetylglucosamine2 oligosaccharide. 
Calnexin/calreticulin can only bind monoglucosylated glycans. Oligosaccharide 
trimming is therefore required. This occurs immediately after the oligosaccharide 
has been transferred to the protein, first by ER glucosidase I, which removes the 
first glucose, and then by glucosidase II which removes the second. The third 
glucose is also trimmed by glucosidase II, but its removal requires separation 
and repositioning of the enzyme with respect to the substrate (Deprez et al, 
2005). This repositioning provides a time window during which the 
monoglucosylated polypeptide can interact with calnexin/calreticulin.  
Glucose trimming must be rapid since calnexin was shown to bind 
proteins not only post-translationally but also co-translationally (Chen et al, 
1995). It has been reported that upon signaling, MAP kinase and casein kinase 2 
dependent phosphorylation of calnexin on Ser-563 allows its association with 
ribosomes (Chevet et al, 1999). We here investigated whether other mechanisms 
control the ability of calnexin to capture its substrates. Calnexin recently came up 
in four large-scale profiling studies of S-acylated proteins (Martin & Cravatt, 
2009; Merrick et al, 2011; Yang et al, 2010; Yount et al, 2010). S-acylation is the 
addition of a fatty acid, generally C16 –palmitate– put possibly also C18–
stearate– (Kordyukova et al, 2010), to cytosolic cysteine residues via a thioester 
bond (Linder & Deschenes, 2007). This modification is mediated by 
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transmembrane palmitoyltransferases harboring a conserved cytosolic DHHC 
domain, 23 of which are present in the human genome (Greaves & Chamberlain, 
2011). In validation of these profiling studies and in agreement with a study 
published during the revision of this manuscript (Lynes et al, 2011), we show that 
calnexin can be palmitoylated on two juxtamembranous cysteines and that this 
modification is mediated by a single palmitoyltransferase, DHHC6, out of the 16 
DHHC enzymes present in the mammalian ER. S-acylation controls the 
localization of calnexin within the ER network, favoring its targeting to the central 
ER. While being a single copy organelle, the ER is indeed compartmentalized 
into a variety of still poorly characterized domains that allow it to fulfill its multiple 
functions, which in addition to protein folding include quality control, synthesis of 
most cellular lipids and storage/control of intracellular calcium (Pendin et al, 
2011). The most apparent, morphologically distinct, ER regions are the highly 
branched tubular network that extends to the cell periphery, the dense 
perinuclear ER, which is formed by sheet-like structures, and the nuclear 
membrane (Pendin et al, 2011; Puhka et al, 2007). The two latter regions 
composed the rough ER, where the RTC complexes reside. 
We found that calnexin is a stable component of the RTC and this 
association relies on calnexin S-acylation. Formation of the calnexin-RTC 
supercomplex leads to the recruitment of the actin cytoskeleton, which further 
stabilizes the assembly. The here-identified acylation-dependent interaction of 
calnexin with the RTC complex allows it to efficiently capture nascent 
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glycosylated polypeptide chains, as they emerge from the translocon, and 
promote their folding. 
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RESULTS 
Calnexin is palmitoylated in the ER on two juxtamembrane cysteines  
Four profiling studies (Martin & Cravatt, 2009; Merrick et al, 2011; Yang et al, 
2010; Yount et al, 2010) identified, with high confidence, calnexin as a S-acylated 
protein in mammalian cells. By immunoprecipitation of either the endogenous or 
tagged calnexin from 3H-palmitate labeled cells, we validated these profiling 
studies: the protein indeed incorporated radiolabeled palmitate, which could be 
removed by hydroxylamine hydrochloride treatment, indicating the involvement of 
a thioester bond (Fig. 1A). This does not exclude that calnexin could be modified 
with either shorter or longer acyl chains as found for certain viral proteins 
(Kordyukova et al, 2010). 3H-palmitate incorporation occurred on both 
juxtamembranous cysteines (Fig. 1B), although somewhat more efficiently on 
Cys-502, which is conserved in most species as well as in the testis-specific 
calnexin homologue, calmegin (Fig. S1).  
In contrast to other lipid modifications, S-acylation is reversible (Greaves & 
Chamberlain, 2011). Proteins such as Ras indeed undergo dynamic (<30 min) 
cycles of palmitoylation-depalmitoylation, and these cycles are crucial for their 
function (Rocks et al, 2010). In contrast to Ras, we found that 3H-palmitate 
turnover on calnexin is slow (Fig. 1C). As a consequence, palmitoylated calnexin 
must accumulate in cells and we indeed found, as described below, that at 
steady state the vast majority of the protein is lipid modified. Palmitoylation of 
calnexin mostly occurs after it has been fully synthesized, since inhibition of 
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protein synthesis with cycloheximide –1 hr prior to 3H-palmitate labeling– only 
mildly affected palmitoylation (18 ± 4% decrease, Fig. 1D).  
 
Calnexin palmitoylation is mediated by DHHC6  
We next identified the palmitoyltransferase that modifies calnexin. PCR analysis 
revealed that all DHHC enzymes, with the exception of DHHC15, 19 and 22, are 
expressed in HeLa cells (Fig. S2A). RNAi duplexes were screened for their 
efficiency in silencing these enzymes (Table S1, Figs. S2A). Silencing of DHHC 
enzymes had minor effects (<25% change) on 3H-palmitate incorporation into 
endogenous calnexin with the exception of DHHC5 and DHHC6 (Fig. 2AB). 
Importantly, 3 different siRNA duplexes against DHHC6 led to a similar decrease 
in calnexin palmitoylation (Fig. 2A) as did an shRNA construct again the non-
coding region of DHHC6 (Fig. S2B). Recomplementation of shRNA treated cells 
with a DHHC6 expression plasmid restored calnexin palmitoylation (Fig. S2B), 
indicating that the observed effect is not due to an off target effect of the shRNA 
or RNAi duplexes.  
3H-palmitate incorporation experiments were also performed upon ectopic 
expression of calnexin-HA. Only DHHC6 silencing led to a marked decrease 
palmitoylation (Fig. 2C and Fig. S2C). We currently have no clear explanation as 
to why DHHC5 silencing affects palmitoylation of endogenous but not ectopically 
expressed calnexin. DHHC6 localizes to the ER (Fig. S2D and (Gorleku et al, 
2011), consistent with the calnexin localization, while DHHC5 is mostly found in 
the Golgi apparatus (Fig. S2D). This however does not exclude its presence in 
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the ER. Since DHHC6 is itself palmitoylated (personal communication, (Gorleku 
et al, 2011), our findings raise the possibility –which will be tested in future 
studies– that DHHC5 palmitoylates DHHC6 or somehow regulates its function. 
We next performed the reverse experiments, we monitored the effect of 
DHHC overexpression. An increase in palmitoylation of endogenous as well as 
ectopically expressed calnexin was observed upon DHHC6 overexpression but 
for none of the other enzymes (Fig. 2D & S2EF). Analysis of the two single 
cysteine calnexin mutants showed that both cysteines are modified by the same 
DHHC6 enzyme (Fig. S2EF). Altogether these observations show that DHHC6 
modifies calnexin on both sites. Consistent with the ubiquitous expression of 
calnexin, we found that the DHHC6 expression is equally broad (Fig. S3A). 
Since many of the experiments described in the present work involve 
DHHC6 silencing, we tested whether DHHC6 siRNA triggers the Unfolded 
Protein Response. A gene profiling analysis using Affimetrix chips revealed that 
while slight changes in expression were observed for GADD45 (-1.3 fold), BiP 
(1.32 fold), XBP1 (1.4 fold), HERP (1.5 fold), these changes are minor in 
comparison to what is observed upon UPR activation. Usually UPR induction 
leads to 4 to 27 fold increase in the expression levels of these genes at the 
mRNA level (Lee et al, 2003). Also we did not observe significant XBP-1 
splicing.  
As a side note, DHHC6 over-expression had no effect on the 
palmitoylation of 4 other proteins known to be S-acylated that transit through the 
ER: the Transferrin receptor (Alvarez et al, 1990), the Wnt co-receptor LRP6 
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(Abrami et al, 2008) and the two anthrax toxin receptors TEM8 and CMG2 
(Abrami et al, 2006) (Fig. S3B), suggesting a certain specificity towards calnexin.  
We next investigated what percentage of the calnexin population is S-
acylated at steady state in HeLa cells. We previously found that 
glycosylphosphatidyl inositol-anchored proteins do not migrate in 2D gels unless 
their lipid moiety has been removed (Fivaz et al, 2000). We inferred that 
palmitoylation might also affect protein migration in 2D gels. Cell extracts from 
control and DHHC6 RNAi treated Hela cells were analyzed by 2D-PAGE followed 
by Western blotting against calnexin, and actin as an internal control. The 
analysis was performed 72 hrs after transfection with DHHC6 siRNA. This did not 
affect the total level of endogenous calnexin when compared to control cells, as 
evidenced by 1D SDS-PAGE (Fig. 2E, left panel; also seen in 2A bottom blot). As 
a striking validation of our strategy, DHHC6 silencing led to a 9.1±0.9 (n=4) fold 
increase of the calnexin signal following 2D-PAGE, while the actin signal was 
unaffected (Fig. 2E, right panels). The increase in calnexin staining upon DHHC6 
silencing demonstrated that at least 90% of cellular calnexin is DHHC6-modified 
at steady state in HeLa cells. Since both sites can be modified (Fig. 1B, 2C, 
S2CEF), depalmitoylation is slow and must be slow on both sites (Fig. 1C), the 
acylated calnexin population revealed by the 2D gel analysis is most likely 
modified on both sites. 
In Fig. 2D, we show that overexpression of DHHC6 leads to a ≈2.5 fold 
increase in the incorporation of 3H-palmitate into calnexin. This might at first 
appear inconsistent with the observation that >90% of calnexin is palmitoylated. It 
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is however important to note that only calnexin molecules with free cysteines can 
incorporate 3H-palmitate. Thus the bulk of cellular calnexin (>90%) is “silent” in 
the 3H-palmitate-incorporation assay and we are monitoring the incorporation of 
3H-palmitate in the remaining population. The rate at which this small population 
of calnexin with free cysteines becomes modified depends on the abundance of 
the enzyme. Thus upon DHHC6 overexpression, incorporation rates increase 
due to an increased amount of the enzyme and so does the signal after our 2 hrs 
standard incorporation (Fig. 2D). 
 
Palmitoylation is predicted to affect the conformation of calnexin 
Using predictive computational methods, we next analyzed whether 
palmitoylation is expected to modify the structure of the transmembrane domain 
(TMD) and/or cytosolic tail of calnexin. Using a topology prediction algorithm 
(Viklund et al, 2008), we first predicted that the membrane embedded residues 
span from Trp-482 to Cys-502. The TMD was then modeled as an ideal α-helix 
based on secondary structure predictions and consistent with the UniProt 
annotations (P27824). We further extended the helical sequence to include 
residues Glu-478 through Ser-510, in order to gain information on the 
conformation of the cytosolic tail. The atomistic transmembrane model was 
inserted into a lipid membrane bilayer and refined using molecular dynamics 
(MD) simulations under physiological-like conditions (e.g. pH ~7, 1 atm, 298 K). 
Only small fluctuations of the secondary structure were observed, which support 
the predicted helical conformation and the match with the hydrophobic interior of 
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the bilayer. The helix tilted by ~30 degrees with respect to the membrane surface 
normal. A distortion of 30±5 degrees in the direction of the helix axis was 
observed at the level of Pro-494 (Fig. 3A), as expected from the helix breaking 
capacity of this residue (Chang et al, 1999). This proline thus breaks the 
rotational symmetry of the helix with respect to its main axis. The full 
conservation of this residue in calnexin and calmegin (Fig. S1) suggests that the 
TMD kink might be of functional importance. 
We next included palmitate moieties at positions Cys-502 (CyP502), Cys-
503 (CyP503) or both (CyP502-503). Palmitoylation did not affect the proline-
induced kink and only marginally affected the helix tilt. The MD simulations 
however predicted a palmitoyl-dependent orientation of the cytosolic tail with 
respect to the helix axis (Fig. 3B). Interestingly, palmitoylation at position 503 is 
predicted to have a more pronounced effect on the conformation of the cytosolic 
tail, indicating that both sites are not equivalent and that one of the two might 
have a regulatory role, predictions that will be tested in the future. Combined with 
the asymmetric nature of the TMD, these simulations raise the interesting 
possibility that palmitoylation may affect the conformation of calnexin, which in 
turn could modify its affinity for membrane domains and/or its capacity to interact 
with proteins in the membrane or in the cytoplasm. 
 
DHHC6 affects calnexin localization 
Palmitoylation of membrane proteins has been proposed to modify their affinity 
for specific plasma membrane micro/nano domains (Charollais & Van Der Goot, 
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2009; Levental et al, 2010). We therefore investigated whether DHHC6 silencing 
would alter the distribution of calnexin. Under control conditions, 
immunofluorescence staining of calnexin is observed in all three major ER 
compartments (Fig. 4A, for additional images see S4A), resembling the staining 
of the soluble lumenal ER chaperone BiP and the transmembrane RTC-
associated protein TRAPα (Fig. 4B, for additional images see S4A).  
When silencing DHHC6, the first observation was a change in cell 
morphology: cells were somewhat less elongated (see Transferrin staining 
bottom of Fig. 4B) and the average cell footprint was ~30% larger (Fig. S5A). The 
nuclear staining and size was however unaltered (Fig. 4A). When viewing 
through confocal stacks of a lawn of cells stained for calnexin (Movie S1A vs. 
Movie S1B), it readily appeared that calnexin staining was lost from the nuclear 
envelope upon DHHC6 silencing.  This was confirmed by quantifying the cells 
showing a nuclear envelope calnexin staining and those that did not, by eye for 
multiple cells over multiple experiments (Fig. 4C). It agreement, the Pearson 
coefficient of co-localization of calnexin with nucleoporins strongly decreased 
upon DHHC6 silencing (Fig. 4D, S4B). Importantly, nuclear membrane 
localization of calnexin was restored upon recomplementation with the DHHC6 
expressing plasmid (Fig. 4C, S4B). Disappearance from the nuclear membrane 
was specific to calnexin, since BiP and TRAPα staining was unaffected by 
DHHC6 silencing (Fig. 4BEF, Fig. S4A). While disappearance from the nuclear 
membrane was obvious, other changes in calnexin staining, in particular in the 
dense and complex perinuclear ER could not be quantified in satisfactory 
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manner. Our interpretation of the change in calnexin distribution is that 
palmitoylation increases the affinity of calnexin for ER sheets, which 
encompasses the entire rough ER and of which the nuclear membrane is the 
most exacerbated form.  
 
Palmitoylation regulates the interaction of calnexin with the RTC 
The observation that DHHC6 expression favors the localization of calnexin to the 
rough ER prompted us to investigate whether calnexin interacts with the RTC 
under steady state conditions. The central translocon component sec61α, as well 
as the translocon associated protein TRAPα and the ribosomal subunit L12 were 
recovered upon immunoprecipitation of endogenous calnexin (Fig. 5A). The 
interaction of calnexin with sec61α and L12 was abolished upon RNAi silencing 
of TRAPα (Fig. 5A), indicating first that the observed interaction of calnexin with 
sec61α and L12 is specific, and not due to bulk co-isolation of membrane 
proteins in detergent/lipid micelles. Moreover the observation indicates that the 
TRAP complex mediates the interaction of calnexin with the RTC. Interestingly, 
TRAPα silencing did not affect the localization of calnexin to the nuclear 
membrane (Fig. S5B), showing that DHHC6-induced perinuclear calnexin 
localization is not due to its interaction with RTCs. 
We next silenced DHHC6 by shRNA treatment for 8 days, in order to 
reduce the cellular pool of S-acylated calnexin. Upon long term DHHC6 silencing, 
co-immunoprecipitation of TRAPα, sec61α and L12 with calnexin decreased by 
≈80% (Fig. 5BC & S6A). Importantly, interaction of calnexin with the RTC was 
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restored by transfection with DHHC6 expressing plasmid (Fig. 5BC & S6A). RTC-
interaction experiments were next carried out using the single and double 
cysteine mutants of calnexin, the S563A mutant -where the phosphorylation site 
promoting ribosome association is modified (Chevet et al, 1999)–, and the P494L 
mutant –where the transmembrane proline (Fig. 3A) is substituted with a 
hydrophobic residue to remove the kink in the TM helix. It should be noted that 
the two latter mutations did not prevent palmitoylation (personal communication). 
The calnexin-RTC interaction was abolished upon mutation of Ser-563 to alanine 
(Fig. 5D & S6B), indicating the importance of this residue even in resting cells 
(Chevet et al, 1999). The RTC-interaction was also severely affected by the 
P494L mutation, pointing out a central role of TMD conformation for the 
association (Fig. 5D). Most strikingly, mutation of either S-acylation site abolished 
the calnexin-RTC interaction (Fig. 5D). Thus not only must calnexin be acylated 
to interact with the RTC, it has to be modified on both cysteines.  
 
Actin is recruited and stabilizes the calnexin-RTC supercomplex 
Stabilization of certain membrane protein complexes/clusters has been found to 
dependent on the actin cytoskeleton (Abrami et al, 2010). We probed whether 
the calnexin-RTC supercomplex interacts with actin. Actin was pulled down upon 
immunoprecipitation of sec61α, TRAPα as well as calnexin (Fig. 6A). The 
interaction between sec61α or TRAPα with actin was strongly diminished upon 
silencing of calnexin (Fig. 6B), indicating firstly that the interaction observed in 
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Fig. 6A is specific and not due to contamination by this abundant protein, and 
secondly that calnexin plays a crucial role in the binding of actin to the RTC. 
The interaction of calnexin with actin was dependent on its palmitoylation 
status as indicated by the decrease in actin association upon DHHC6 silencing 
(Fig. 6C). Calnexin-actin interaction was restored upon transfection with the 
DHHC6-expressing plasmid (Fig. S6C). The importance of palmitoylation for 
calnexin-actin interaction was confirmed by the weak association of the single 
and double cysteine calnexin mutants with actin (Fig. 6D). The fact that DHHC6 
silencing had a more pronounced effect than mutation of the palmitoylation sites 
might be due to indirect effects of unidentified ER DHHC6 targets. 
Altogether the above observations raised the possibility that actin can only 
be recruited to calnexin-RTC supercomplex when it is fully assembled. To test 
this possibility, we stripped off ribosomes from the ER membrane by a 15 min 
puromycin treatment. Strikingly, calnexin then no longer interacted with either the 
translocon or actin (Fig. 6E), indicating that indeed actin can only bind to the fully 
assembled supercomplex. Moreover, the puromycin effect shows that calnexin is 
recruited to the translocon only when the ribosome has docked.  
In reverse, we investigated whether actin polymerization was important for 
the stabilization of the supercomplex. Inhibiting actin polymerization by a short 
latrunculin A treatment was sufficient to decrease the interaction of calnexin with 
L12, TRAPα and sec61α (Fig. 6EF), while nocodazole, which disrupts 
microtubules, had no effect (Fig. 6EF).  
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Palmitoylation of calnexin promotes the folding of glycosylated proteins 
Finally we investigated whether the calnexin-RTC interaction is important for the 
lectin chaperone function. We first analyzed the effect of silencing either 
calnexin, TRAPα or DHHC6 on the production –i.e. an overall read out for 
synthesis, folding and secretion– of total glycoproteins. Silencing of any of the 
three proteins led to a significant decrease in total glycoproteins as monitored by 
a 20 min 35S Cys/Met pulse, followed by precipitation with the lectin, concavalin A 
(Fig. 7A & S7A). The 30% drop in detected glycoproteins is consistent with the 
known redundancy of the folding systems for glycoproteins (Braakman & Bulleid, 
2011). As a control, we monitored the production of cytosolic, i.e. non-N-
glycosylated, proteins and found that silencing of calnexin, TRAPα or DHHC6 
had no effect (Fig. S7B).  
Next, we analyzed the production of two specific glycoproteins: a soluble 
version of alkaline phosphatase (SEAP: secreted alkaline phosphatase), which 
provides a quantitative readout upon secretion –again used as an overall read 
out for synthesis, folding and secretion– (Lakkaraju et al, 2008) and the prion 
protein PrP, which undergoes a characteristic change in migration by SDS-PAGE 
upon folding and maturation (Fons et al, 2003).  
DHHC6 silencing led to a 30% decrease in SEAP secretion (Fig. 7B). In 
contrast, secretion of the non-glycosylated protein bovine preprolactin, a well-
studied protein translocation substrate (Lakkaraju et al, 2008), was not affected 
by DHHC6 silencing  (Fig. S7C). 
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To assess the direct involvement of calnexin and the importance of its 
palmitoylation status, we silenced calnexin by shRNA and recomplemented the 
cells with WT or mutant calnexins (Fig. S7D). Calnexin silencing led to a 70% 
drop in SEAP secretion, which could be restored to >80% of control cells, upon 
recomplementation with the WT protein (Fig. 7C). In contrast, no recovery was 
observed upon recomplementation with palmitoylation-deficient calnexin (AA 
mutant) (Fig. 7C), while single cysteine and S563A mutants led to a very weak 
recovery (Fig. 7C). Altogether, these observations show that DHHC6-mediated 
palmitoylation of calnexin on both cysteines is required for optimal folding and 
secretion of SEAP.  
We next monitored maturation of GFP-tagged prion protein (PrP), which 
upon expression in control cells migrates by SDS-PAGE predominantly in a 
mature form with some precursor form (Fig. 7D). Neither the mature nor the 
precursor PrP forms were detectable by Western blotting upon silencing of 
calnexin, TRAPα or DHHC6. Synthesis of PrP precursor was however unaffected 
by the calnexin, TRAPα or DHHC6 silencing as determined by a 5 min 35S-pulse 
labeling of PrP (bottom of panel Fig. 7D and quantification Fig. S7E). Thus, in the 
absence of these proteins, PrP is rapidly degraded following synthesis. A similar 
rapid post-translational degradation of PrP was observed upon Latrunculin A 
treatment (Fig. 7E), further supporting that proper folding of PrP requires the fully 
assemble calnexin-RTC supercomplex. 
Altogether the above experiments indicate that S-acylation controls the 
ability of calnexin to acts as a chaperone. To address this point specifically, we 
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monitored the binding of monoglucosylated substrates to calnexin. DHHC6 was 
silenced or not using shRNA and newly synthesized proteins were metabolically 
labeled. After detergent solubilizing the cells, calnexin-substrate complexes were 
isolated by immunoprecipitation against calnexin. As a control, cells were 
pretreated or not with castanospermine (CST), a specific inhibitor of α-
glucosidases which prevents the generation of monoglucosylated proteins 
(Hammond & Helenius, 1994). Importantly castanospermine had no effect on 
either palmitoylation or depalmitoylation of calnexin (not shown). Also 
catanospermine did not alter the cellular localization of calnexin nor its interaction 
with the RTC (not shown). 
After a pulse of metabolic labeling, a well-defined pattern of calnexin 
substrates was detected in control cells, which was absent in castanospermine 
treated cells (Fig. 7F, left panel). DHHC6 silencing led to a drastic decrease in 
the amount of calnexin-bound substrates, without affecting their pattern (Fig. 7F, 
left panel). Even when the metabolic pulse was followed by a chase period, 
substrate binding could not be observed in DHHC6 silenced cells, indicating that 
not only co- but also post-translational binding was defective. To confirm that 
non-acylated calnexin is unable to capture its substrates, substrate binding of the 
AA palmitoylation deficient mutant calnexin was monitored in comparison to WT, 
in cells where endogenous calnexin was silenced by shRNA. As shown in Fig. 7F 
(right panel), palmitoylation deficient calnexin failed to bind its substrates. This 
observation however does not necessarily mean that the capacity of calnexin to 
binding monoglucosylated proteins per se is affected. It reveals that in the 
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cellular context, calnexin must be palmitoylated and be part of the RTC complex 
to grab its substrates. If substrates are not captured co-translationally, they either 
aggregate or are handled by other folding systems in the ER, but calnexin will not 
bind them pots-translationally. 
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DISCUSSION 
Calnexin is a transmembrane chaperone that aids in the folding of glycosylated 
proteins by binding to monoglucose residues on the branched N-linked 
oligosaccharide and thus protects the protein from aggregation. The interaction 
of calnexin with nascent chains has been observed more than 15 years ago 
(Chen et al, 1995), but little information was available on the specific 
mechanisms that may facilitate this co-translational interaction. We here report 
that calnexin is a stable component of the RTCs –as is the OST– leading to the 
formation of a supercomplex. This interaction occurs via the translocon-
associated complex TRAP. Based on X-ray crystallography and single particle 
analysis, a model of the translocon complex has been proposed wherein TRAPα 
interacts with sec61α, the latter interacting via the opposing face of the molecule 
with sec61ß (Menetret et al, 2008). Our findings thus allow a rough positioning of 
calnexin in this supercomplex, sandwiching TRAPα between calnexin and the 
translocon (Fig. 8).  
 Formation and stabilization of calnexin-RTC supercomplex requires 
several factors. As previously described (Chevet et al, 2010), Ser-563 is critical 
possibly due to its phosphorylation. The kinked conformation of the 
transmembrane domain also influences the interaction, as indicated by the 
disruptive effect of mutating the highly conserved TM Pro-494. Importantly, 
calnexin must be palmitoylated. 
Despite the presence of 12 (Ohno et al, 2006) to 16 (our unpublished 
observations in Hela cells) palmitoyltransferase in the mammalian ER, the S-
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acylation of calnexin is performed by a single enzyme, DHHC6. The involvement 
of a single DHHC enzyme was rather unexpected since these enzymes are 
thought to have broad overlapping specificities at least for soluble substrates 
(Greaves & Chamberlain, 2011). Also in contrast to soluble substrates such as 
Ras, calnexin does not undergo dynamic cycles of palmitoylation-
depalmitoylation. As a consequence, at steady state, the S-acylated form –and 
most likely the dual acylated form– accumulates and almost the entire pool of 
cellular calnexin is modified in resting cells as shown by our 2D gel analysis. The 
observed slow rate of palmitate turnover might be due to the close proximity, and 
possibly even embedding, of the cysteine residues in the membrane, which 
would render them inaccessible to cytosolic thioesterases, of which only one has 
so far been identified, the soluble enzyme APT1 (Dekker et al, 2010). Recently it 
has been observed for ß1-adrenergic receptor that the susceptibility of cysteines 
to thioesterases indeed correlates with distance from the transmembrane domain 
(Zuckerman et al, 2011).  
 S-Acylation of calnexin promotes its interaction with the RTC in two ways: 
Firstly, palmitoylation affects the ability of calnexin to interact with the TRAP 
complex, possibly by influencing the conformation of the TMD and/or the 
cytosolic tail as suggested by the MD simulations. Secondly, palmitoylation 
favors the association of calnexin with the nuclear membrane, and probably with 
sheet-like ER structures in general. Calnexin spans the membrane only once and 
it is therefore unlikely that it has any membrane curvature sensing capacity. 
Since protein and lipid compositions are likely different in ER tubules vs. ER 
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sheets (Shibata et al, 2010; Shibata et al, 2008), palmitoylation may favor the 
partitioning of calnexin to sheet-like structures, in a manner similar to raft-
partitioning of transmembrane proteins at the plasma membrane (Levental et al, 
2010). Calnexin has also been shown to localize to Mitochondrial Associated 
Membranes (MAM), sites of interaction between the ER and mitochondria (de 
Brito & Scorrano, 2010; Myhill et al, 2008). During the revision of this manuscript, 
localization of calnexin as well as of TMX, a transmembrane ER-thioredoxin, to 
MAMs was reported to depend on palmitoylation of these two type I membrane 
proteins (Lynes et al, 2011). Future studies should elucidate whether and how S-
acylation dependent localization of calnexin to the various ER domains is 
controlled. 
Interestingly, once fully assembled, the calnexin-RTC supercomplex 
recruits the actin cytoskeleton, which in turn is required to stabilize the assembly. 
While in yeast and plants where cortical ER is known to move along actin cables 
(Du et al, 2004), few reports describe interactions between actin and the ER in 
animal cells (Du et al, 2004). Actin is well known to interact with the nuclear 
envelope via Nesprins, large transmembrane proteins involved in nuclear 
positioning and nuclear-envelope architecture (Lombardi et al, 2011). However 
interactions with the rest of the ER have not been reported with the exception of 
a study showing that actin controls the diffusion of newly synthesized 
glycoproteins in the ER lumen and thereby reduces aggregation during folding 
(Nagaya et al, 2008). Our observations raise the possibility that this is due to the 
handling of these glycoproteins by the calnexin-RTC supercomplexes.  
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Altogether the present work leads to a model where DHHC6-mediated S-
acylation favors the partitioning of calnexin into the rough ER and, in addition, 
allows it to interact with RTC components leading to the formation of a 
supercomplex, which subsequently recruits the actin cytoskeleton, the 
polymerization of which in turn is required to maintain the assembly (Fig. 8). 
When the nascent polypeptide chain emerges from the translocon pore, it arrives 
into a folding prone microenvironment: the OST and BiP initially keep it in an 
unfolded state to allow optimal N-glycosylation and also await the full synthesis of 
folding units. By being an integral part of the ribosome-translocon supercomplex, 
calnexin is ideally positioned to capture its client protein following appropriate 
glucose trimming, protecting the protein from aggregation as it undergoes 
oxidative folding, further benefiting from the calnexin-associated oxidoreductase 
ERp57. 
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MATERIALS AND METHODS 
Cell culture, plasmids, transfections and real time-PCR 
HeLa cells (ATCC) were grown in complete Modified eagles medium (MEM) 
(Sigma) at 37°C supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, penicillin and streptomycin. RPE1 cells were grown in complete 
Dulbeccos MEM (DMEM) (Gibco) supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, penicillin and streptomycin. Mammalian expression 
plasmids harboring human C-terminally tagged Calnexin-HA and Calnexin-GFP 
were generated by cloning the calnexin cDNA into pCDNA3 vector bearing the 
HA tag or GFP. Constructs to express single or double point mutation of calnexin 
were generated using the Quickchange (Stratagene) strategy following 
manufacturer instructions. Isoform 1 of human tumor endothelial marker 8 
(TEM8) cDNA tagged with a HA epitope was cloned in the pIREShyg2 vector. 
Plasmid encoding human myc-LRP6 was provided by Dr. G. Davidson. GFP-PrP 
was provided by Dr. Chiara Zurzolo. PPL-3f was provided by Dr. Katharina Strub. 
Human DHHC cDNA were cloned in pCE puro-His-myc or flag expressing 
plasmids. Plasmids were transfected into cells for 24 or 48 hrs (2 µg cDNA/9.6 
cm2 plate) using Fugene (Roche Diagnostics Corporation). For control 
transfections, we used an empty pCDNA3 plasmid. shRNA against calnexin were 
generated from the p.Super.Retro.Puro vector containing the hairpin insert 
against the following target sequence present at the 3’ UTR of calnexin gene: 5’-
gagcttgatctgtgatttc- 3’(Table S1). As a control, we used shRNA against the target 
sequence in firefly luciferase gene: 5′-CGTACGCGGAATACTTCGA-3′. shRNA 
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against DHHC6 was generated by cloning the hairpin insert against the target 
region in the 3´UTR of DHHC6: 5’CCTAGTGCCATGATTTAAA3’ (Table S1). 
For the real-time PCR, RNA was extracted from a 6 well dish using the RNeasy 
kit (Qiagen). 1 mg of the total RNA extracted was used for the reverse 
transcription using random hexamers and superscript II (Invitrogen). A 1:40 
dilution of the cDNA was used to perform the real-time PCR using SyBr green 
reagent (Roche). mRNA levels were normalized using three housekeeping 
genes: TATA-binding protein (TBP), β-microglobulin and β-glucoronidase (GUS). 
Total RNA of different human tissues was obtained from Amsbio.  
 
Antibodies and Reagents  
Polyclonal antibodies against calnexin were generated against the C-terminal 
peptide: CDAEEDGGTVSQEEEDRKPK in rabbit; rat antibodies against purified 
CMG2 were produced in our laboratory; anti-HA and anti-GFP were from Roche; 
Anti-flag M2 antibody from Sigma; anti-HA-agarose conjugated beads, used for 
the immunoprecipitations from Roche (Applied Science, IN); anti-calnexin 
monoclonal and anti-myc antibodies from Santa Cruz; anti-actin antibodies from 
Millipore; anti-transferrin receptor antibodies from Zymed; anti-Nuclear Pore 
Complex Proteins (Mab414), anti-Sec61α, anti-BiP antibodies from Abcam. Anti-
L12 antibodies were provided Dr. K. Strub. Anti-TRAPα antibody was provided by 
Dr. R. Hegde. Protein G-agarose conjugated beads were from GE Healthcare, 
HRP secondary antibodies were from Pierce, and Alexa-conjugated secondary 
antibodies from Molecular Probes. Latrunculin A (used at a concentration of 
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0.4mg/ml for 30 min or 1h) and Nocodazole (used at a concentration of 10µM for 
30 min or 1h) were from Sigma. Castanospermine was purchased from 
Calbiochem and used at a concentration of 1mM. Puromycin was purchased 
from Calbiochem and used at a concentration of 200µM for 15 min to strip the ER 
of ribosomes in HeLa cells. 
 
Immunoprecipitation and RNAi experiments 
 siRNA against human DHHC were purchased from Qiagen (see Table S1). As 
control siRNA we used the following target sequence of the viral glycoprotein 
VSV-G: 5’attgaacaaacgaaacaagga 3’. For gene silencing, Hela cells were 
transfected for 72 hrs with 100 pmol / 9.2 cm2 dish of siRNA using interferrin 
(Polyplus) transfection reagent.  
For all immunoprecipitations unless specified, cells were lysed 30 min at 4°C in 
IP buffer (0.5%NP40, 500 mM Tris-HCl pH 7.4, 20 mM EDTA, 10 mM NaF, 2 mM 
benzamidine, and a cocktail of protease inhibitors, Roche) followed by 
centrifugation for 3 min at 2000 g. The supernatants were precleared with protein 
G-agarose conjugated beads and incubated 16 h at 4°C with antibodies and 
beads. The beads were washed for three times with the IP buffer and 
resuspended in the sample buffer (2x) after the final wash. The samples were 
heated at 95°C for 5 min and migrated on SDS-PAGE. Western blotting was 
performed using the iBlot (Invitrogen) according to the manufacturers 
instructions. Quantification of the blots was done either using the typhoon imager 
or Image J software. 
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Radiolabeling experiments 
To monitor palmitoylation, HeLa cells transfected with either the wild type or 
mutant calnexin constructs were incubated for 2hrs at 37°C in IM (Glasgow 
minimal essential medium buffered with 10 mM Hepes, pH 7.4) with 200 µCi /ml 
3H palmitic acid (9,10-3H(N)) (American Radiolabeled Chemicals, Inc). The cells 
were washed and the cell lysate was extracted followed by immunoprecipitation 
with tag specific antibodies in the case of exogenously expressed calnexin and 
calnexin antibody in case of endogenous protein. After the washes, beads were 
incubated for 5 min at 90°C in non-reducing sample buffer (2x) prior to SDS-
PAGE. After the SDS-PAGE, the gel was incubated with a fixative solution (25% 
isopropanol, 65% H2O, 10% acetic acid), followed by a 30 min incubation with 
signal enhancer Amplify NAMP100 (Amersham). The dried gels were exposed to 
a Hyperfilm MP (Amersham). Chemical removal of S-palmitoylation was 
performed by treating cell extracts for 1h at room temperature with 1M 
hydroxylamine hydrochloride  (Sigma) pH 7.2. Protein synthesis was blocked by 
1hr treatment with 10 µg/ml cycloheximide (Sigma) at 37°C. 
To monitor the ability of calnexin to bind substrates, HeLa cells were first 
transfected with the shRNA against calnexin for 7 to 9 days. After 96hrs, cells 
were retransfected with either the wild type or the AA mutant calnexin for 48 hrs.  
Cells were pretreated or not for 1h with 1mM castanospermine (CST), a specific 
inhibitor of α-glucosidases and pulse labeled with 100µCi/ml 35S-
methionine/cysteine for 10 min followed by a 3 min chase in the presence or 
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absence of drug. Cells were harvested in an isotonic HEPES buffer (pH-6.8) 
containing 2%CHAPS and protease inhibitor cocktail. Post nuclear supernatants, 
obtained by centrifuging the sample at 10000g for 10 min, were submitted to 
immunoprecipitation overnight with anti-calnexin antibody followed by incubation 
with protein G agarose beads for 2hrs at 4°C. 
To monitor the synthesis and maturation of GFP-PrP protein, HeLa cells 
transfected with GFP-PrP under different experimental conditions were labeled 
with 100µCi/ml 35S-methionine/cysteine for 30 min. The cells were then lysed in 
lysis buffer composed of 0.1M Tris-HCl pH-8 and 1% SDS. The cell lysate was 
heated at 95°C for 10 min with occasional stirring until the lysate is no more 
viscous. The cleared lysate was diluted in the RIPA buffer (150 mM NaCl, 1% 
NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl [pH 8], 1 mM EDTA, and 
1X protease inhibitor cocktail). Immunoprecipitation was performed using an anti-
GFP antibody. 
For all the experiments, samples were analyzed by 4-12% gradient SDS-PAGE, 
followed by fixing and drying of the gels. The radiolabeled products were 
revealed using Typhoon phosphoimager and the quantified using the Typhoon 
Imager (Image QuantTool, GE healthcare). 
 
Glycoprotein analysis 
Fractionation of newly synthesized glycoproteins was performed in 35mm dishes. 
Cells were metabolically labeled with 50 µCi/ml of 35S- Methionine / cysteine mix 
for 20 min, followed by a wash with ice-cold PBS. Cytosolic proteins were 
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extracted by treating the cells with 150µg/ml of digitonin in KHM buffer (110 mM 
KAc, 20 mM Hepes, pH 7.2, 2 mM MgAc2) for 5min. After the recovery of 
cytosolic extract, the cells were washed once again in the KHM buffer and 
resuspended in 500 µl of the IP buffer to extract the non-cytosolic proteins. The 
glycoproteins were separated from the non-cytosolic protein fraction by 
incubation with Con-A beads (GE Healthcare) for 1hr. Equal amounts of total 
protein were loaded on the Con-A beads from all the samples Con-A beads 
selectively bind to the glycoproteins. The beads were washed for three times with 
the IP buffer and the glycoproteins were eluted by 300 µl of IP buffer containing 
0.25 M α-methyl- D-mannopyranoside. Both the cytosolic and glycoprotein 
fractions were migrated on 4-20% SDS PAGE gradient gels. The gels were fixed, 
dried and further analyzed for autoradiography. 
 
Calnexin complementation and SEAP Assay 
For the complementation assay, HeLa cells were transfected with shRNA against 
calnexin and the transfected cells were selected by treating with puromycin 
(3µg/ml) for 24h. At 72h post transfection the cells were split into 6 well plates 
and the day after were transfected with the control plasmid, the wild type or the 
mutant calnexin cDNAs and when required with the pSEAP2 reporter plasmid.  
SEAP assay was performed using Great EscAPe SEAP Chemiluminescence Kit 
2.0 (Clonetech). The cell medium was changed 24h before the SEAP assay was 
done in order to monitor the SEAP secreted for 24h when the RNAi or the over 
expression is most effective. Assay was performed in a 96 well plate, using 15µl 
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of the growth medium according to the manufacturers instructions. The 
Chemiluminescence signal was collected by Spectra Max multiwell plate reader 
and the data was analyzed by Soft Max Pro 5 software. 
 
 DHHC6 recomplementation 
For the complementation assay HeLa cells were transfected with shRNA against 
DHHC6 followed by selection of transfected cells by treating with puromycin 
(3µg/ml) for 24h. The cells were further transfected on day6 with the cDNA 
expressing human DHHC6 without its 3´UTR for complementation. The 
functional assays were performed on day 8 to analyze the restoration of 
phenotypes observed by the loss of DHHC6. 
 
Immunofluorescence microscopy 
Immunofluorescence in HeLa was done as described previously with the 
exception of the fixative used. To label the plasma membrane of the cells, the 
cells were treated with 5µg/ml of FITC labeled Transferrin (Molecular probes) for 
1h at 4°C. This was followed by washes at 4°C and fixation. Cells were fixed and 
permeabilized with methanol at -20°C for 4 min. Cells were further labeled with 
the appropriate primary antibody, followed by labeling with Alexa-conjugated goat 
anti-rabbit or anti-mouse IgG (405nm, 488nm, 568nm). The nuclei were stained 
by Hoechst dye. Images were acquired using a 63x lens on LSM-710 Laser 
scanning microscope (Carl Zeiss Microimaging, Inc.). The Zen software was 
used for the processing of the images and the 3D stacks. The movie animations 
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and the summation of the z-stacks were done using the Image J software. To 
calculate the Pearson correlation coefficient, four different regions on the nuclear 
membrane were analyzed for 15 cells. Each condition was subjected to a total of 
60 regions and the Pearson coefficient was calculated using Coloc 2 plugin in 
FIJI software. 
 
Molecular dynamics simulations  
We used molecular dynamics (MD) simulations to characterize the calnexin TM 
domain at the atomistic level in the membrane environment. As a first step, the 
ideal helical TM model was inserted and equilibrated in a 60x60 Å2 Palmitoyl 
Oleoly Phosphatidyl Choline (POPC) membrane patch (Humphrey et al, 1996) to 
characterize its structure and dynamics in a phospholipid bilayer. A Palmitoyl 
group was then covalently linked to C502 and C503 sulfur atoms to form the 
single and double palmitoylated calnexin models. 
All simulations were performed using the NAMD (Phillips et al, 2005) engine, in 
combination with the CHARMM27 force field brooks, including CMAP 
corrections. TIP3P water (Jorgensen et al, 1983) parameterization was used to 
describe the water molecules. The spatial overlapping of lipid molecules and 
protein were removed and the resulting protein-membrane system was solvated 
in variable-size water box, at a salt concentration of 150 mM NaCl. The periodic 
electrostatic interactions were computed using the particle-mesh Ewald (PME) 
summation with a grid spacing smaller then 1 Å. All systems were first minimized 
by 2000 conjugate gradient steps, and subsequently gradually heated from 0 to 
 33	  
300 K in 800 ps with a constraint on the protein backbone scaffold. Finally, the 
systems were equilibrated for 10 ns at 300K. Free molecular dynamics of all 
equilibrated system were run for not less than 50 ns with a 2 fs integration time 
step using the RATTLE algorithm applied to all bonds, and trajectories collected 
for analysis. Constant temperature (300K) was imposed by using Langevin 
dynamics (Brunger & Brooks, 1984), with damping coefficient of 1.0 ps. Constant 
pressure of 1 atm was maintained with a Langevin piston dynamics (Feller et al, 
1995) 200 fs decay period and 50 fs time constant. 
 
Statistical analysis  
All experiments were performed at least 3 times, independently. Two-tailed T-
tests were performed to evaluate the significance of the data. 
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FIGURE LEGENDS 
Figure 1: Calnexin is palmitoylated in the ER  
A: HeLa cells were transfected or not (endogenous) for 48h with Calnexin-WT-
GFP or Calnexin-AA-GFP. Cells were incubated with 3H-palmitic acid for 2h. Cell 
extracts were treated or not with 1M hydroxylamine hydrochloride pH 7.2 (1h at 
room temperature) prior to immunoprecipitation using anti-calnexin or anti-GFP 
antibodies. Immunoprecipitates were split into two, run on SDS-PAGE and 
analyzed by autoradiography or Western blotting.  
B: HeLa cells were transfected 24hrs with Calnexin-WT-HA or Calnexin-CA-HA, 
Calnexin-AC-HA or Calnexin-AA-HA, labeled with 3H-palmitic acid and analyzed 
as in A by autoradiography or Western blotting (anti-HA). See Figure S1 for 
positions of the cysteines. Bottom panel: autoradiograms were quantified using 
the Typhoon Imager. Errors correspond to standard deviations (n=5).  
C: Non-transfected HeLa cells were labeled as in A. The cells were then washed 
and incubated in the normal medium and cell lysis was performed at different 
time points followed by immunoprecipitation as described in A. Samples were 
analyzed by autoradiography and the quantification was performed using the 
Typhoon imager (n=3).  
D: HeLa cells were pretreated or not with cycloheximide (CHX) for 1 hr followed 
by 3H-palmitic acid labeling in the presence or absence of the drug. 
Immunoprecipitation was preformed using anti-calnexin antibodies Samples were 
analyzed by autoradiography and Western blotting (anti-calnexin). Quantification 
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was performed using the Typhoon Imager. Errors correspond to standard 
deviations (n=3).  
 
Figure 2: Calnexin is palmitoylated by DHHC6 
A: HeLa cells were transfected for 72hrs with different DHHC siRNA or control 
siRNA (Ctrl). Cells were incubated with 3H-palmitic acid for 2h prior to 
immunoprecipitation using anti-calnexin antibodies. Immunoprecipitates were 
split into two, run on SDS-PAGE and analyzed either by autoradiography (3H-
palmitate) or Western blotting (anti-calnexin).  
B: Autoradiograms and western blots from (A) were quantified using the Typhoon 
Imager. Errors correspond to standard deviations (n=4). ** p< 0.01. For the 
identity of the siRNAs see Table S1, for their efficiency see Fig. S2A 
C: HeLa cells were transfected 72hrs with Calnexin-WT-HA or Calnexin-CA-HA, 
or Calnexin-AC-HA and DHHC siRNAs, labeled with 3H-palmitic acid. 
Immunoprecipitates using anti-HA antibodies were split into two, run on SDS-
PAGE gels and analyzed either by autoradiography or Western blotting (see Fig. 
S2C). Autoradiograms and western blotting were quantified using the Typhoon 
Imager. Errors correspond to standard deviations (n=4).  
D: HeLa cells were transfected 24hrs with human DHHC cDNA, labeled with 3H-
palmitic acid. Immunoprecipitates using anti-Calnexin antibodies were analyzed 
and quantified as in B (n=4). For analysis of cysteine mutants see Fig. S2EF. 
 E: HeLa cells were transfected for 72hrs with DHHC6 siRNA or control siRNA 
(Ctrl). Left panel: cells were labeled with 3H-palmitic acid as analyzed as in A. 
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Right panel: 50 µg of cell extracts were analyzed using 2D-gel ZOOM IPGRunner 
system (Invitrogen) followed by Western blotting using anti-calnexin and anti-
actin antibodies.  
 
Figure 3: Modeling of the effect of palmitoylation on calnexin conformation 
A: The atomistic models of the helical transmembrane domain of calnexin were 
equilibrated in a solvated DOPC membrane bilayer using molecular dynamics 
simulations. Cys502, Cys503 and Pro494 are shown in licorice representation. 
The approximate position of the membrane bilayer is shown by dashed lines. 
B: Palmitoylation affects the orientation of the cytosolic tail of calnexin with 
respect to the axis of the transmembrane helix. 
 
Figure 4: Effect of DHHC6 silencing on calnexin localization 
A: HeLa cells were transfected with either a control shRNA or shRNA against 
DHHC6 for 8 days, fixed in methanol and stained with anti-calnexin and anti-
nucleoporin antibodies. Bar: 10 µm. 
B: HeLa cells grown on cover slips were transfected for 72h with either control 
siRNA or siRNA against DHHC6 and were incubated or not with fluorescent 
Transferrin, washed, fixed in methanol and immunostained with any one of the 
following antibodies: calnexin, BiP, TRAPα. Each image represents the sum of all 
the stacks taken in z-axis.  To visualize more cells see Fig. S4A. Bar: 10 µm. 
C: HeLa cells were transfected with either a control shRNA or shRNA targeting 
DHHC6 for 8 days. On day 6 the cells were transfected either with an empty 
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vector or human DHHC6 cDNA bearing a myc tag for complementation. The cells 
were fixed and stained with anti-calnexin, anti-nucleoporin and Hoechst dye. The 
cells were analyzed manually for presence or absence or restoration of the 
nuclear membrane staining of calnexin. 50 cells were analyzed per condition per 
experiment. Error bars represent the standard deviation (n=3). 
D: The cells from A were imaged and the Pearson correlation coefficient for 
colocalization between calnexin and nucleoporins was determined by monitoring 
15 cells/experiment from each condition (n=3). 
E,F: Confocal stacks of cells treated as in B were analyzed manually and the 
number of cells showing nuclear or no nuclear membrane staining for calnexin 
(C), BiP (D) or TRAPα was determined. Three independent experiments were 
analyzed and 50 cells were counted for each experiment. Error bars represent 
standard deviations. 
 
Figure 5: Palmitoylation regulates the interaction of Calnexin with the RTC. 
A: HeLa cells were transfected for 72h with either the control siRNA or a siRNA 
against TRAPα. Immunoprecipitates against anti-calnexin were analyzed by 
western blotting for calnexin, TRAPα, Sec61α and L12. 
B: HeLa cells were transfected for 8 days with control shRNA or the shRNA 
against DHHC6. On day 6 the cells were retransfected either with an empty 
plasmid (lanes 1&2) or with a plasmid expressing DHHC6. The cells were lysed 
on day 8 and immunoprecipitated using mouse anti-calnexin antibody. 
Immunoprecipitates were analyzed SDS-PAGE followed by western blotting 
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against calnexin, TRAPα, Sec61α and L12. For the analysis of the total cell 
lysates see Fig. S6A. 
C: Western blots from  (B) were quantified using Image J software and the error 
bars represent the standard deviation (n=3). 
D: HeLa cells were transfected for 48 hrs with either WT, single or double 
cysteine calnexin mutants, mutant of the phosphorylation calnexin site S563A or 
of the TMD proline. Immunoprecipitates against anti-HA were analyzed by 
western blotting against: TRAPα, Sec61α, Sec62, Sec61β and L12. For the 
analysis of the total cell lysates see Fig. S6B. 
 
Figure 6: Calnexin palmitoylation promotes interaction with actin 
A: HeLa cells lysates were immunoprecipitated using either anti-Sec61α anti-
TRAPα, anti-calnexin antibodies or no antibody. The immunoprecipitates were 
analyzed by western blotting against actin, calnexin and TRAPα. Blotting against 
Sec61α could not be performed as it migrates at the same molecular weight as 
the antibody heavy chain.  
B: HeLa cells were transfected for 6 days with either shRNA against luciferase or 
shRNA against calnexin and lysed.  After immunoprecipitation against Sec61α 
(left panel) or TRAPα (right panel), samples were analyzed by western blotting 
against actin, calnexin and TRAPα. As in A, Sec61α could not be probed.  
 C: HeLa cells were transfected with a control siRNA, siRNA against DHHC6 or 
DHHC3 and lysed. Immunoprecipitates against calnexin were analyzed by 
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Western blotting against calnexin and actin. Quantification was performed using 
the Typhoon Imager. Error bars correspond to standard deviations (n=4).  
 D: HeLa cells were transfected or not for 48h with cDNA expressing calnexin-HA 
WT, double or single cysteine mutants, and lysed Immunoprecipitates against HA 
were analyzed by western blotting against HA and actin and quantified using 
Typhoon Imager. Error bars correspond to standard deviations (n=4). Total cell 
extracts (TCE) were probed for actin. 
E: HeLa cells were treated for 30 min at 37°C with either DMSO, Latrunculin A or 
Nocodazole or 15 min with puromycin or water, which was used as a control. The 
cells were lysed and immunoprecipitated with rabbit anti-calnexin antibody. The 
immunoprecipitates and the total cell extracts were migrated on SDS-PAGE 
followed by western blot to reveal calnexin, actin, TRAPα and L12 (n=3). 
F: The treatment with Latrunculin A and Nocodazole was performed as in E. 
Immunoprecipitates against calnexin were analyzed by SDS-PAGE and followed 
by western blotting against calnexin, TRAPα and Sec61α. Western blots were 
quantified using Image J software and the error bars correspond to standard 
deviations (n=3). 
 
Figure 7: Palmitoylation of Calnexin promotes the folding of glycosylated 
proteins 
A: HeLa cells were transfected with either the control siRNA or siRNAs against 
DHHC6, TRAPα or DHHC3 for 72h and shRNA against calnexin for 144h. The 
cells were labeled with 35S-Methionine/Cysteine for 20 min. The cytosolic 
 46	  
proteins were isolated by semi-permeabilizing the cells using digitonin. The 
glycoproteins were separated from the non-cytosolic fraction by using Con-A 
agarose beads. The glycoprotein fraction was run on SDS-PAGE and the 
radiolabeled products were visualized by Typhoon phosphoimager. The 
radiolabeled lanes were quantified using the Typhoon Imager and the histograms 
were plotted as the ratio of glycoproteins to the cytosolic proteins in each sample. 
The error bars represent the standard deviation (n=4). *** p<0.001. For the 
autoradiograms of glycoproteins and cytosolic proteins see Fig. S7A, B. 
B: HeLa cells were cotransfected with either 1) control siRNA or siRNA against 
DHHC6 and the pSEAP2 plasmid or 2) an empty vector or the DHHC6 
expressing vector and the pSEAP2 plasmid. The cell medium was replaced with 
fresh medium in all the plates so that the SEAP secreted in the final 24h was 
quantified. The SEAP secreted was normalized to the total amount of protein 
present in each sample and expressed as percentage of SEAP secreted by the 
control. * p<0.05. 
C: HeLa cells were transfected with either the control shRNA or the shRNA 
against calnexin. At 96h post transfection, cells were transfected with the 
pSEAP2 vector and either empty vector or the vector expressing WT or mutant 
calnexins. At 120h post transfection, the cell medium was replaced with fresh 
medium in order to assess the SEAP accumulated in the last 24h. The measured 
SEAP values were normalized to the total amount of the protein present in each 
sample and the values were plotted as a percentage of the shLuc transfection. 
***: p<0.001, ** : p<0.01, * :  p<0.05. 
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D: HeLa cells were either cotransfected with GFP-PrP and the control siRNA or 
the siRNA targeting DHHC6, TRAPα. Calnexin was silenced by shRNA and 
GFP-PrP was transfected 96h after the shRNA transfection. Cell lysates were 
prepared and equal amounts of the proteins were analyzed by western blotting 
for GFP, calnexin, TRAPα, Sec61α, GAPDH. PrPp indicates the precursor form of 
GFP-PrP and PrPm the mature form.  
E: HeLa cells were transfected with GFP-PrPwt for 24h, treated with either 
DMSO, Latranculin A or Nocodazole for 30 min at 37°C and prior to 30min 35S-
methionine-cysteine pulse labeling in the presence of the drugs. The cell lysates 
were immunoprecipitated with anti-GFP antibody and the immunoprecipitates 
were analyzed by SDS-PAGE followed by Typhoon phospho-imaging. PrPp 
indicates the precursor and PrPm the mature form of the GFP-PrP protein. 
F: To monitor the binding of calnexin to the substrates HeLa cells were either 
treated with shRNA against DHHC6 (left panel) or shRNA against calnexin (right 
panel). The cells depleted of endogenous calnexin were recomplemented with 
either the WT or AA mutant. The cells were pulse labeled with 35S-methionine-
cysteine for 10 min followed by a chase of 3 min either in the presence of 
castanospermine or not. The lysate was immunoprecipitated using anti calnexin 
antibody and migrated on a SDS-PAGE followed by fixation and drying of the 
cells. The radiolabelled products were revealed by typhoon phosphoimager. 
 
Figure 8: Molecular consequences of calnexin palmitoylation 
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When its palmitoylation sites are free, calnexin preferentially localizes to the 
peripheral tubular ER. Upon S-acylation by DHHC6, calnexin partitions 
preferentially into the rough ER and associates with TRAPα, altogether ensuring 
that calnexin efficiently interacts with the RTC. Once the calnexin-RTC has 
assembled into a supercomplex, actin is recruited and stabilizes the assembly. In 
this configuration, calnexin is positioned to efficiently grab nascent glycoproteins 
as they emerge from the translocon pore, acquire their N-linked glycan from 
which the 2 external glucoses have been trimmed. 
 
 	  








